SV News
26 October 2021Portfolio NewsXilio Therapeutics Announces Closing of Initial Public Offering- 21 October 2021Portfolio NewsXilio Therapeutics Announces Pricing of Initial Public Offering
- 18 October 2021Portfolio NewsXilio Therapeutics Announces FDA Clearance of Investigational New Drug Application for XTX202 for the Treatment of Solid Tumors
27 September 2021Portfolio NewsFIERCE BIOTECH NAMES MESTAG THERAPEUTICS AS ONE OF ITS “FIERCE 15” BIOTECH COMPANIES OF 2021- 16 September 2021Portfolio NewsXilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX101 for the Treatment of Patients with Solid Tumors
15 September 2021Portfolio NewsPulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA- 3 August 2021Portfolio NewsMestag Therapeutics Extends Seed Financing to $45 Million and Welcomes New Investors Forbion, GV (formerly Google Ventures) and Northpond Ventures
- 19 July 2021SV NewsSV Health Investors becomes a signatory of the Investing in Women Code signifying it’s commitment to contribute to improving female entrepreneurs’ access to tools, resources and finance.
22 June 2021Portfolio NewsImbria Pharmaceuticals Announces enrolment of the first 10 patients in IMPROVE-DiCE, an Exploratory Phase 2 Study Investigating the impact of IMB-1018972 on Cardiac Energetics, Metabolism and Function in Patients with Type 2 Diabetes
22 June 2021Portfolio NewsAlchemab Therapeutics Appoints Douglas A. Treco, PhD as Chief Executive Officer
12 June 2021SV NewsKate Bingham is recognised in this year's Queen’s Birthday Honours List- 27 May 2021Portfolio NewsPulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945
